Recursion Pharmaceuticals’ stock took a hit despite announcing positive safety data from its Phase 2 trial for REC-994, an investigational treatment for Cerebral Cavernous Malformation (CCM). While the trial met its primary endpoint for safety and tolerability, the company reported no significant improvements in patient outcomes at the 12-month mark. However, secondary endpoints showed encouraging trends in reduced lesion volume and hemosiderin ring size in patients on the highest dose.